Last week, CNBC-TV18 had reported that Mylan is looking to sell part of its 5.64% stake in Biocon Ltd through a block deal. The floor price for the transaction has been fixed at ₹378.50 per share, which is at a 7.9% discount to the current market price.
Mylan acquired the stake after Biocon completed its acquisition of the company’s holding in Biocon Biologics in January 2026 through a combination of a share swap and cash consideration. As part of the transaction, Mylan received a preferential allotment of Biocon shares, taking its stake in the company to more than 6%.
Fourth Quarter Results
Biocon reported a strong set of numbers in the fourth quarter of FY25, with net profit after exceptional items surging 154% to ₹344.5 crore, compared to ₹135.5 crore a year earlier. On a like-for-like basis, net profit rose 162%. The figure was also well above CNBC-TV18’s poll estimate of ₹167.7 crore.
ALSO READ | Biocon shares gain after partner wins insulin contracts worth 225 million Ringgit in Malaysia
Revenue grew 12.8% year-on-year (YoY) to ₹4,417 crore, beating expectations of ₹4,168.6 crore.
Biocon reported a strong set of numbers in the fourth quarter of FY25, with net profit after exceptional items surging 154% to ₹344.5 crore, compared to ₹135.5 crore a year earlier. On a like-for-like basis, net profit rose 162%. The figure was also well above CNBC-TV18’s poll estimate of ₹167.7 crore.
Revenue grew 12.8% year-on-year (YoY) to ₹4,417 crore, beating expectations of ₹4,168.6 crore.
Operating performance remained strong, with EBITDA rising 17.7% YoY to ₹1,078.2 crore versus ₹915.9 crore in the same quarter last year. This was ahead of the projected ₹943.3 crore.
ALSO READ | Biocon shares in focus after announcing Biologics unit buyout, fund raise approval
Shares of Biocon Ltd ended at ₹413.10, down by ₹5.35, or 1.28%, on the BSE.
First Published: Jul 13, 2026 6:49 PM IST
